TOM FORD Announces Appointment of Haider Ackermann as Creative Director
4.9.2024 16:30:00 EEST | Business Wire | Press release
TOM FORD announces the appointment of Haider Ackermann as Creative Director, effective immediately.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904332237/en/
Haider Ackermann appointed Creative Director, TOM FORD. (Photo Credit: Ethan James Green)
In his new role, Ackermann will assume the creative leadership across all TOM FORD fashion categories, including menswear, womenswear, accessories, and eyewear, and guide the creative vision for the overall brand. TOM FORD is owned by The Estée Lauder Companies Inc. (NYSE:EL) with the fashion business licensed to the Ermenegildo Zegna Group (NYSE:ZGN) and the eyewear business licensed to Marcolin SpA.
Founder Tom Ford said, “I have long been a great fan of Haider’s work. I find both his womenswear and menswear equally compelling. He is an incredible colorist, his tailoring is sharp, and above all he is modern. We share many of the same historical references, and I could not be more excited to see what he does with the brand. I suspect that I will be the first on my feet to applaud after his show in March.”
A French national born in Bogotá, Colombia, Ackermann's upbringing spanned Ethiopia, Chad, Algeria, The Netherlands, and Belgium, where he studied fashion at the Royal Academy of Fine Arts in Antwerp. Known for blending luxurious fabrics with impeccable tailoring, Ackermann has garnered acclaim for his avant-garde, yet wearable designs favored by celebrities.
“It is with tremendous pride that I will seek to honor the legacy of Tom Ford, a man I have long admired and have the utmost respect for,” said Ackermann. “I am much looking forward to what lies ahead.”
Ackermann's first collection will debut at Paris Fashion Week in March 2025. He will be based in Paris, reporting to Guillaume Jesel, President and CEO, TOM FORD and Luxury Business Development, The Estée Lauder Companies, and to Lelio Gavazza, CEO, TOM FORD FASHION, Ermenegildo Zegna Group.
“Haider stands out as one of the world's most visionary and inspiring talents in fashion. He draws on his deep affinity for global culture and the arts to create arresting fashion and memorable emotional connections. He is the ideal steward to usher TOM FORD into the future," said Jesel.
“I am extremely pleased to welcome Haider as Creative Director of TOM FORD. His unparalleled creativity, which is aligned with the brand's DNA, as well as his renowned experience in luxury will be instrumental in driving the fashion business forward during its next important phase of expansion. Working alongside the talented team at TOM FORD FASHION, Haider’s modern vision, for both men’s and women’s wear, will be essential as we advance and execute the many projects we have in development,” said Gavazza.
About TOM FORD
TOM FORD is a global design house offering exceptional luxury products across women’s and men’s fashion, accessories, eyewear and beauty. Founded in 2005 by Tom Ford, the brand has a presence in more than 100 markets globally and is widely recognized as the architect of luxury glamour. In 2023, The Estée Lauder Companies became the sole owner of the TOM FORD brand and all its intellectual property. In connection with the acquisition, The Estée Lauder Companies established long term licenses with Ermenegildo Zegna Group for TOM FORD FASHION and Marcolin for TOM FORD EYEWEAR.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904332237/en/
Contacts
Press Contact:
Giuseppe Torrisi
TOM FORD, Global Communications Director
Giuseppe.Torrisi@tomfordfashion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom